Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the availability of pancreatic enzyme replacement therapy.

The Department is continuing to work with all suppliers of pancreatic enzyme replacement therapy (PERT) to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production. Through these discussions we have managed to secure additional volumes for 2025 for the United Kingdom. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market.

We have widely disseminated comprehensive guidance to healthcare professionals, including National Health Service trusts, general practices, and pharmacies, about these supply issues, which provide advice on how to manage patients whilst there is disruption to supply. The Department has issued additional management advice to healthcare professionals which directs clinicians to consider unlicensed imports when licensed stock is unavailable, and which includes actions for integrated care boards to have local mitigation plans in place and implemented to ensure that no patient is left without PERT.

The Department will continue to work closely with the manufacturers to resolve the issues as soon as possible, to ensure patients have continuous access to medicines. The Department also meets regularly with the affected patient advocacy groups and charities, clinicians, and other relevant stakeholders, to ensure they are kept informed on the latest supply picture and any communications issued. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.